Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition
On May 15, 2017, Interpace Diagnostics Group, Inc. (the Company)
issued a press release announcing its results of operations and
financial condition for the quarter ended March 31, 2017. The
full text of the press release is set forth as Exhibit 99.1
attached hereto and is incorporated herein by reference.
The information in Item 2.02 of this Current Report on Form 8-K,
including Exhibit 99.1, is being furnished and shall not be
deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act) or otherwise
subject to the liabilities of that section, nor shall it be
deemed to be incorporated by reference in any registration
statement or other document filed under the Securities Act of
1933, as amended, or the Exchange Act, except as otherwise stated
in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| 99.1 | Press Release dated May 15, 2017 (furnished to Item 2.02). |
| Exhibit Number | Description | |
| 99.1* | Press Release dated May 15, 2017. |
* Filed herewith
About Interpace Diagnostics Group, Inc. (NASDAQ:IDXG)
Interpace Diagnostics Group, Inc., formerly PDI, Inc., is focused on developing and commercializing molecular diagnostic tests principally focused on early detection of high potential progressors to cancer and leveraging the latest technology and personalized medicine for patient diagnosis and management. The Company operates through molecular diagnostics segment. It offers molecular tests, such as PancraGen, which is a pancreatic cyst molecular test that can aid in pancreatic cyst diagnosis and pancreatic cancer risk assessment utilizing its PathFinder platform; ThyGenX, which assesses thyroid nodules for risk of malignancy, and ThyraMIR, which assesses thyroid nodules risk of malignancy utilizing a gene expression assay. Through its molecular diagnostics business, the Company provides diagnostic options for detecting genetic and other molecular alterations that are associated with gastrointestinal and endocrine cancers, which are focused on early detection of cancer. Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) Recent Trading Information
Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) closed its last trading session up +0.34 at 2.73 with 6,925,458 shares trading hands.
